JCO Precision Oncology Conversations

JCO PO Editor-in-Chief Emeritus Dr. James Ford and Founding PI, ASCO TAPUR Study, Dr. Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study and its relationship with the journal. Host Dr. Rafeh Naqash and guests discuss the inception/history of the TAPUR study, its future, and advances in precision medicine over the past decade.
LINK TO FULL TRANSCRIPT

In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology" by Schwartz and colleagues.
LINK TO FULL TRANSCRIPT

JCO PO authors Dr. James Hadfield, Dr. Grace Yiqing Zhao, and Dr. Julia Elvin at AstraZeneca share insights into the JCO PO article, "Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?" Host Dr. Rafeh Naqash and guests discuss emerging evidence that cfDNA methylation profiling provides sensitive, specific signals of tissue injury across multiple organs and clinical contexts.
LINK TO FULL TRANSCRIPT

In this episode of JCO PO: Article Insights, host Jiasen He summarizes the article, "Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study," by Roberts and colleagues.
LINK TO FULL TRANSCRIPT

JCO PO author Dr. Emily Miao at Mass General Brigham Cancer Institute shares insights into the JCO PO article, "Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers." Host Dr. Rafeh Naqash and Dr. Miao discuss the clinicogenomic characteristics and treatment outcomes of patients with ALK+ squamous and adenosquamous lung cancers and how these outcomes compare to those of patients with ALK+ adenocarcinoma treated with first-line alectinib.
LINK TO FULL TRANSCRIPT